Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Next Generation Sequencing Bioinformatics Heats up: Nearing $1000 Genome Sparks Soaring Data Output

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
Frost & Sullivan: Healthcare innovation hinges on managing escalating amounts of data priming to more than triple the market.

The decreasing cost of genome sequencing lends momentum to the global next-generation sequencing (NGS) informatics market. As affordability drives adoption of genome sequencing in multiple end-user segments, an enormous output of NGS data to store and analyze is an overwhelming result. While primary and secondary data analysis tools are likely to become a commodity as pipelines standardize, the high-value tertiary data analysis segment used for biological interpretation and clinical reporting will drive revenue growth.

New analysis from Frost & Sullivan’s (http://www.lifesciences.frost.com) Global Next Generation Sequencing Informatics Market finds the market earned revenue of $170 million in 2012 and estimates this to reach $580 million in 2018 at an impressive compound annual growth rate (CAGR) of 22.7 percent. The research covers commercial primary and secondary data analysis tools, storage, computing, commercial biological interpretation and reporting tools, NGS informatics services, and laboratory information management systems across North America, Europe, Asia, and rest of world.


“With sequencing data production forecast to grow at a CAGR of more than 75 percent between 2012 and 2018, researchers will need efficient NGS informatics solutions to manage, analyze and interpret this escalating amount of data,” said Frost & Sullivan Life Sciences Senior Industry Analyst Christi Bird. “As the number of applications for NGS continues to grow, the implementation of NGS informatics will go up.”

However, customers employ NGS for a broad range of applications, and there is no ideal product for NGS informatics. Therefore, customers may struggle to identify the appropriate tools for their needs. The wide variety of free public domain and commercial tools provided by the 100 plus competitors in this market has also led to low barriers to entry, ever-intensifying competition, and commoditization in certain product segments.

Moreover, given the array of public and open source software available along with readily accessible internal bioinformatics resources, NGS users are often hesitant to make additional investments in commercial informatics tools. Therefore, beyond the challenges of commoditization and standardization, suppliers must convince NGS users their commercial tools are better than free ones.

“As the market matures and informatics prices fall, competitors will rely not just on the expanding volume of users and NGS data developed but also on the high-value interpretation sector of the market to sustain profits globally,” opined Bird. “Suppliers that can develop high-value, simple and streamlined turnkey solutions will find success.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gene Expression Profiling Drives Personalized Medicine Worldwide
Large amounts of information generated by gene expression profiling will increase implementation of data management tools.
Tuesday, June 10, 2014
Frost & Sullivan gives an overview of the Global Automated Biobanking market
Robotics to aid and drive long term vision of truly personalised medicine
Friday, May 11, 2012
Frost & Sullivan: Finding Healthcare's 'Holy Grail'
Faced with escalating treatment costs and pressure to be affordable while searching for efficiency and better quality, hospitals are turning towards Health IT (HIT) for assistance where patient care is no longer the sole responsibility of doctors and nurses alone.
Friday, July 09, 2010
Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
Human Evolution Driven by Viruses
Study finds surprising percentage of protein adaptions in humans have been driven by viruses.
Earliest Sign of Alzheimer's Development Discovered
Researchers have identified the first physiological signs of late-onset Alzheimer's disease, underlining the importance of computational power in neurology.
Computational Method Offers Significant Boost in Finding New Cancer Targets
MIT and ARIAD Pharmaceuticals team have identified evidence of significant cancer mutations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!